Difference between revisions of "Team:UofC Calgary"

Line 261: Line 261:
 
To creating a cost effective and continuous delivery system for IR protection during space travel, we have designed a transdermal patch for the delivery of a modified version of BBI (mBBI) through the skin. The patch hosts recombinant <i>Bacillus subtilis</i> cells that express mBBI with a transdermal tag that allows the peptide to travel through the layers of the skin and into the bloodstream for dispersal throughout the body. This recombinant protein is fused to a <i>B. subtilis</i>-specific secretory tag, which permits the peptide to be secreted into the growth medium. Using <i>B. subtilis</i> for the production of mBBI allows for constant delivery and resolves the issue of sinusoidal pharmacokinetics. This long term, continuous delivery is also cost effective and minimizes waste. Ultimately, our transdermal delivery patch allows for the administration biotherapeutics within an efficient and practical system, while maintaining the flexibility of modularity, as <i>B. subtilis</i> could be used to produce a multitude of various peptides or small molecules.
 
To creating a cost effective and continuous delivery system for IR protection during space travel, we have designed a transdermal patch for the delivery of a modified version of BBI (mBBI) through the skin. The patch hosts recombinant <i>Bacillus subtilis</i> cells that express mBBI with a transdermal tag that allows the peptide to travel through the layers of the skin and into the bloodstream for dispersal throughout the body. This recombinant protein is fused to a <i>B. subtilis</i>-specific secretory tag, which permits the peptide to be secreted into the growth medium. Using <i>B. subtilis</i> for the production of mBBI allows for constant delivery and resolves the issue of sinusoidal pharmacokinetics. This long term, continuous delivery is also cost effective and minimizes waste. Ultimately, our transdermal delivery patch allows for the administration biotherapeutics within an efficient and practical system, while maintaining the flexibility of modularity, as <i>B. subtilis</i> could be used to produce a multitude of various peptides or small molecules.
 
</p>  
 
</p>  
 +
 +
<p style="color: #FFFFFF">References</p>
 +
 +
<p style="color: #FFFFFF">Dittmann, K.H., Mayer, C., and Rodemann, H.P. (2003). Radioprotection of normal tissue to improve radiotherapy: the effect of the Bowman Birk protease inhibitor. <i>Current Medicinal Chemistry - Anticancer Agents, 3</i>(5), 360-363.</p>
 
                                 </div>
 
                                 </div>
 
                             </div>
 
                             </div>

Revision as of 01:47, 14 October 2016

iGEM Calgary 2016

Our Project

  • Project Description

    Mars and the cosmos are a tantalizingly close goal for Mankind to reach in the next century; however, there are several glaring problems that we must hurdle to reach such an objective. Radiation is chief among them. Each year on Earth, individuals receive 2.4 mSv of ionizing radiation (IR), which is easily tolerated by the human body. Unfortunately, without the protection of the magnetosphere, astronauts in space are exposed to high levels of IR in the range of 50 to 2000 mSv. This level of radiation causes the accumulation of deleterious double strand breaks in DNA. Despite current research into methods of IR protection, many solutions such as radiation shield coating are quite expensive, especially to transport to space.

    Biological solutions, such as the use of ingestible or injectable radioprotectors, are subject sinusoidal pharmacokinetics. The therapeutic is delivered once, and although it may be effective initially, it will be degraded over time by the body, dropping its efficiency rate. This results in the need of re-administration of a drug to increase its activity in the body, resembling a sinusoidal curve. Certain naturally-occurring proteins and peptides, such as the Bowman-Birk Protease Inhibitor (BBI), have been found to confer protection against DNA damage in cells exposed to ionizing radiation. Previous studies have shown that BBI increases the survival rate of cells significantly after they are irradiated by augmenting endogenous DNA repair mechanisms (Dittmann et al., 2003).

    To creating a cost effective and continuous delivery system for IR protection during space travel, we have designed a transdermal patch for the delivery of a modified version of BBI (mBBI) through the skin. The patch hosts recombinant Bacillus subtilis cells that express mBBI with a transdermal tag that allows the peptide to travel through the layers of the skin and into the bloodstream for dispersal throughout the body. This recombinant protein is fused to a B. subtilis-specific secretory tag, which permits the peptide to be secreted into the growth medium. Using B. subtilis for the production of mBBI allows for constant delivery and resolves the issue of sinusoidal pharmacokinetics. This long term, continuous delivery is also cost effective and minimizes waste. Ultimately, our transdermal delivery patch allows for the administration biotherapeutics within an efficient and practical system, while maintaining the flexibility of modularity, as B. subtilis could be used to produce a multitude of various peptides or small molecules.

    References

    Dittmann, K.H., Mayer, C., and Rodemann, H.P. (2003). Radioprotection of normal tissue to improve radiotherapy: the effect of the Bowman Birk protease inhibitor. Current Medicinal Chemistry - Anticancer Agents, 3(5), 360-363.

Our Project

Project Description

Our Experiments

Modelling

Human Practices

Click to learn more about each part of our project

About us

The 2016 U of C Calgary iGEM team is a multidisciplinary team based out of the University of Calgary. Out team is made up of undergraduate students from all years of study form the broad backgrounds of Biology, Microbiology, Biomedical Sciences, Bioinformatics, and Chemical and Mechanical Engineering. We are based out of the O'Brien Centre Labs within the U of C's Health Science Centre.

Our Sponsors

iGEM

iGEM is an international competition promoting synthetic biology as a means to solve social, economic and humanitarian problems around the globe. The iGEM Jamboree is held in Boston annually. In 2016, over 300 teams are competing against each other.

Latest Entries

BBI & KTI Have Arrived!

Lorem ipsum dolor sit amet ipsum sit, consectetuer adipiscing elit sit amet

Fully Trained!

Lorem ipsum dolor ipsum sit ipsum amet, consectetuer sit adipiscing elit ipsum elit elit ipsum elit

Read More

Latest Pictures

View More

Find us

Located in Calgary, Alberta, Canada.

  • University of Calgary
  • syed.jafri2@ucalgary.ca